(Reuters) – Purdue OxyContin Maker Pharma LP has reached a multibillion dollar trial agreement with some complainants focused on solving thousands of lawsuits over its alleged role in U. opioid crisis, Reuters reported Wednesday, citing people who know the content.
The value of the settlement could be valued up to $ 12 billion, which they said, which would add to the largest settlement of its kind in the pharmaceutical history of the United States.
The following are some of the foremost legal arrangements relating to the pharmaceutical industry.
– Merck & Co $ 4.85 billion, 2007 – Three years after arthritis arthritis drug had been removed from the market for safety concerns and after various product liability trials, Merck agreed to pay nearly $ 5 billion to most of the 60,000 issues resolved Vioxx drew heart attacks and strokes. Kenneth Frazier, who was a general adviser and oversight of the litigation and settlement strategy, was successful with CEO Merck on January 1, 2011.
– American Home Products Corp. (name changed to Wyeth) $ 3.75 billion, 2000 – Three years after the weight loss mix, known as meat-fen and used by millions of Americans, is removed from the market because one was Both drugs are linked to serious heart valve problems, which may be fatal, a federal judge approved a $ 3.75 billion class action settlement. The agreement asked that money be distributed to those who injured the drug, with payments up to $ 1.5 million depending on the severity of the injury or length of use. Included in total was $ 1 billion set aside to pay for future medical checks.
– GlaxoSmithKline Plc $ 3 billion, 2012 – GSK agreed to plead guilty and pays $ 3 billion in criminal and civil penalties for promoting drugs such as Paxil and Wellbutrin antidepressants for unapproved uses, without safety data. Avandia diabetes drugs and kick-back provide doctors pay.
– Takeda Pharmaceutical Co. Ltd. $ 2.4 billion, 2015 – The Japanese drug maker agreed to pay $ 2.4 billion to solve thousands of laws by alleging that his drug actos was bladder cancer. Takeda did not acknowledge liability and said the claims were invaluable but they agreed to resolve “complex litigation uncertainties.”
– Pfizer Inc. $ 2.3 billion, 2009 – The arrangement for 13 inappropriate marketing of drugs included a $ 1.3 billion criminal fine to promote the drug now withdrawn arthritis pain for unapproved uses. Six whistleblowers were exposed to the practices. Bextra was acquired by Pfizer with the purchase of Pharmacia. The case included the promotion of Neurontin anti-seizure drugs.
– Johnson & Johnson $ 2.2 billion, 2013 – J&J agreed to the removal of civil and criminal investigations in the promotion of illicit uses of anti-cyclical drugs Risperdal and Invega and for the payment of kick-back to pharmacists.
– Abbott laboratories $ 1.6 billion, 2012 – Resolution of civil and criminal allegations that Abbott had advanced an anti-seizure drug for uses not approved by US regulators. Abbott agreed that he pleaded guilty to a single breach of misconduct on the Food, Drugs and Cosmetic Act and entered into a Corporate Integrity Agreement with the US government to oversee its compliance program for five years.
– Eli Lilly and Co. The resolution included a criminal fine of $ 515 million and up to $ 800 million in civil settlement with the federal and state governments of the United States.
Reporting by Bill Berkrot; Edited by Leslie Adler
(TTTranslate tags) US (t) CHANGE (t) PHARMA (t) SETTLEMENT (t) HISTORY (t) FACTBOX (t) Company News (t) Fact Boxes (t) Health / Medicine (t) Japan (t) Process Judicial / Court Cases / Court Decisions (t) Pain Management (t) Asia / Pacific (t) Europe (t) Public Health (t) Crime / White Crime Crime / Corporate Crime (t) Pharmaceuticals and Medical Research ( TRBC) (t) Medical Regulatory Issues (t) United Kingdom (t) Drug / Substance Misuse (t) United States of America